Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical...
Transcript of Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical...
![Page 1: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/1.jpg)
Multi-RegionalClinicalTrials(MRCTs):PracticeandIssuesofMulti-RegionalClinicalTrials’GlobalAcceptance
Withthanksto:BarbaraBiererMilaOwen
RebeccaLi,PhDExecutiveDirector
![Page 2: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/2.jpg)
Disclaimer:
• TheopinionscontainedhereinarethoseoftheauthorsandarenotintendedtorepresentthepositionofBrighamandWomen'sHospitalorHarvardUniversity.
• TheMRCTCenterissupportedbyvoluntarycontributionsfromfoundations,corporations, internationalorganizations,academicinstitutionsandgovernmententities(seewww.MRCTCenter.org)andwellasbygrants.
• Wearecommittedtoautonomy inourresearchandtotransparency inourrelationships.TheMRCTCenter—and itsdirectors—retainresponsibilityandfinalcontrolofthecontentofanyproducts,resultsanddeliverables.
10/13/16 2
![Page 3: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/3.jpg)
OurMission
Engagediversestakeholderstodefineemergingissuesinglobalclinicaltrialsandtocreateandimplementethical,actionable,andpracticalsolutions.
10/13/16 3
![Page 4: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/4.jpg)
AgendaMRCTs:Science,andRegulations
• WhyMRCTs?• MRCTexpectations,benefitsandchallenges• Internationalandregulatoryconsiderations• Rationaleforacceptanceofforeigncountrydata• Bridgingstudyrequirements
10/13/16 4
![Page 5: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/5.jpg)
AgendaMRCTs:Science,andRegulations
• WhyMRCTs?• MRCTexpectations,benefitsandchallenges• Internationalandregulatoryconsiderations• Rationaleforacceptanceofforeigncountrydata• Bridgingstudyrequirements
10/13/16 5
![Page 6: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/6.jpg)
TwoStagesinNewDrugDevelopment1.Learningstage(phase1andphase2trials):
– Safety,Dosingselection,Patientpopulationselection– Efficacyscreeningusingsurrogateendpoint
2. Confirmingstage(phase3trials,e.g.,MRCT):– Efficacy(consistencyacrosssubgroups),– Safety,dosing,– Benefit/risk ratio
6 6
StagesofDrugDevelopment
![Page 7: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/7.jpg)
MRCTs:PrinciplesandLogic
• MRCTsrarelyemployed inPhase1and2trials• MRCTsinPhase3clinicaltrials:
– Expeditedrugdevelopmentandrisk/benefitanalysis– Betterbasisforsubsequentgeneralizationofthefindings– Maintainsamestandardsformultipleregulatorysubmissions– Reduceunnecessarycostanddelay
• Assumptionofconsistency:thatregionsareequivalentandnosignificantdifferencesexist– Understandingofandstatistical
assessmentofconsistency– Impactofintrinsic/extrinsicfactorson
outcome
10/13/16 7
Coordinator
Region 1 Region 2 Region 3
Site 1 Site 2 Site 9 Site 10Site 11Site 12Site 13Site 7 Site 8Site 3 Site 4 Site 5 Site 6
![Page 8: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/8.jpg)
MRCT:Definition
10/13/16
Aclinicaltrialwithacommonprotocol,involvingdifferentcentersandparticipantsenrolledfromdifferentregions(countries),wherethedata
collectedisanticipatedtobeanalyzedasawhole.*
*adaptedfromICH-E3
Coordinator
Region 1 Region 2 Region 3
Site 1 Site 2 Site 9 Site 10 Site 11 Site 12 Site 13Site 7 Site 8Site 3 Site 4 Site 5 Site 6
![Page 9: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/9.jpg)
WhyMRCTs?
• Morepatientpopulationsavailableforstudy• Potentiallytreatmentnaïveindividuals• Maybeonlypracticalwayofaccruingsufficient
numbersofparticipantswithinagiventimeframe• Morerapidenrollmentfromwiderpopulationand
differingclinicalsituations• Potential importantinternalcomparisonsanddatato
defendgeneralizationofthefindings• Simultaneousratherthansequentialsubmissionsfor
registration
![Page 10: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/10.jpg)
DrugLaginClinicalDevelopmentAmongVariousRegulatorySubmissionsStrategiesinJapan
ClinicalPharmacology&TherapeuticsVolume95,Issue5,pages533-541,8NOV2013DOI:10.1038/clpt.2013.223http://onlinelibrary.wiley.com/doi/10.1038/clpt.2013.223/full#cptclpt2013223-fig-0001
MRCTsIncreaseEfficiencyandReduceDrugLag
![Page 11: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/11.jpg)
Yourroleasregulatorisbecomingincreasinglycomplex
MAXIMIZEBENEFITBringbeneficialdrugstopatients
asquicklyaspossible
Maintainincentivesforcompanies&researchers to
innovate
DECREASERISKEnsuresafetyof
patientsbykeepingineffective/unsafedrugsoutofthe
market10/13/16 ©MRCT 11
HowdoMRCTsfitin?
![Page 12: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/12.jpg)
FocusonMRCTsExaminingtheKeyIssues
Trueinconsistencyvs Randomvariation
Countryspecificpatient
requirements
DefiningRegion
Disparateresultsbyregion/roleofethnicity
Regulatorcapacityandtraining
Differingendpointsrequiredby
region
Dataquality
10/13/16 ©MRCT 12
![Page 13: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/13.jpg)
MRCTs:notwithoutprecedentorguidance
• ICH-E5EthnicFactorsinAcceptabilityofForeignClinicalData– Bridgingstudies:
• Allowsextrapolationofdatafromoneregiontoanother
• Expeditesdrugdevelopmentprogram
• Formulti-regionalclinicaltrialtoserveasabridgingstudyforaparticularregion,shouldbe“persuasive”
• Therefore,MRCTshouldbeplannedwithsufficientnumbersofsubjectstohaveadequatepowertohaveareasonablelikelihoodofshowinganeffect ineachregionofinterest
• Iftoserveasbridgingstudy,provideefficacyandsafetybyregion,andexamineconsistencyofeffectsacrossregions(andifdose-responserelationshipthenefficacyandsafetywithinandacrossregions.
10/13/16 ©MRCT 13
![Page 14: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/14.jpg)
MRCTs:PrecedentandGuidance
• ICH-E3StructureandContentofClinicalStudyReport– Individualcenterresultsshouldbepresentedwhenappropriate(sufficient
#,etc.)
– Treatment-by-center (country)analysisshouldbeexplored
– “…Anyextremeoroppositeresultsamongcentersshouldbenotedanddiscussed,consideringsuchpossibilitiesasdifferences instudyconduct,patientcharacteristics,orclinicalsettings.”
• ICH-E9StatisticalPrinciplesforClinicalTrials– Protocolimplementationshouldbeclearandsimilaratallsites
– Procedures standardized,variationreduced
– “…theusualsamplesizeandpowercalculationsdependupontheassumptionthatthedifferences between thecomparedtreatmentsinthecentersareunbiasedestimatesofthesamequantity.”
10/13/16 ©MRCT 14
![Page 15: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/15.jpg)
MRCTDesign
• Implicationsfor– Studydesign– Choiceofendpoint(s)
• Particularlyproblematicifregulatoryguidancediffersastowhatisacceptablestudydesignorendpoint
If results of an MRCT are positive with acceptable benefit/risk ratio for a new drug, then further region subgroup analysis can be explored through different statistical methods depending on the level of “consistency” required.
10/13/16 ©MRCT 15
Howisconsistencyconsidered?
Howis“subgroup”defined?
![Page 16: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/16.jpg)
AgendaMRCTs:Science,andRegulations
• WhyMRCTs?• MRCTexpectationsanddesign• MRCTchallenges• Internationalandregulatoryconsiderations• Rationaleforacceptanceofforeigncountrydata• Bridgingstudyrequirements
10/13/16 16
![Page 17: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/17.jpg)
CurrentChallengesGloballyontheStatusofMRCTs
• No clear global guidance on MRCTs
• Individual countries have published statements on topics related to MRCTs (including China)
• Use of foreign clinical data varies across countries
• Need for bridging studies or separate studies in the region’s population– Ethnic factors and considerations (ICH 5)
– Subgroup analysis
![Page 18: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/18.jpg)
MRCT:Ethnicvariationvs.RandomVariation(continued)
• ManyofusmakeanaprioriassumptionofMRCTsthatnooronlyminorregionalvariationexists
• Nodatanowtopredictwhichtrials(ordrugs,interventions,devices)arelikelytodemonstratesubgroupdifferencesandnowaytodistinguishtrueconsistencyissuesorethnicvariationfrommererandomvariability.
10/13/16 ©MRCT 18
![Page 19: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/19.jpg)
MRCTChallenges
•Whiletheresultsofmostmulti-nationaltrialsdonotdemonstrateanyinternalinconsistencyamongregionsorcountries,onoccasioninconsistencybetweenregionsorcountries isobservedandmaybedueto:
• Inaccuraciesindiagnosesordifferences innaturalhistoryorstageofdisease
• Differences inmedicalorstudypractice(s)orconcurrentmedications• Differences inlifestyle,diet,orenvironmentalinfluences• Truegenetic,racial,orethnicdifferences amongtheregions• Randomvariation• Inconsistencyatsite,regionorcountrylevel
![Page 20: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/20.jpg)
AgendaMRCTs:Science,andRegulations
• WhyMRCTs?• MRCTexpectations,benefitsandchallenges• Internationalandregulatoryconsiderations• Rationaleforacceptanceofforeigncountrydata• Bridgingstudyrequirements
10/13/16 20
![Page 21: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/21.jpg)
ComparisonTableforForeignDataAcceptance
10/13/16 ©MRCT 21
ForeignData LocalParticipants DataAnalysisU.S. Foreigndataallowedif
relevant andapplicable.Notrequiredbutsometimespreferred
Recommendsdecreasingdatavariability
China Accepted(exceptforbiologics),butlocaldatarequired.
Preciserequirementsforeachphase.100pairs.Draft ProvisionsforDrugRegistrationissued.
Trend consistencyacrosslocalandglobalpopulation
India AllowedexceptforphaseItrialsandvaccinetrials.
Precise requirementsforeachphase.
Nospecificrequirements
E.U AcceptedifincompliancewithmemberandEUlaw.
Notrequired. Intrinsic/Extrinsicfactorsconsideredwhenextrapolatingdata.
Japan Accepted unlessissueswithlocalparticipantordatarequirements.
15-20%required. Datamustbe consistentacrosslocalandglobalpopulation– specificmethods
Aus,Can, S.Africa,Brazil,Mex,Turkey,S.Korea
No specificrequirements Notrequired Nospecificrequirements
![Page 22: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/22.jpg)
MRCTs:AsiaPacificCountries
• Simplerregulatoryframeworks– Korea,Taiwan,HongKong,Singapore,Australia,NewZealand
• Morerigorousrequirementsandprocedures– Japan– requiresspecificparticipantnumbersandconsistencyacrossglobaltrialandlocally
– ImpactfulnewlegislationwithshortimplementationwindowØ China:IMCTapplicationinChinaØ India:PhaseIallowedonlyifIndiancompany,bridgingrequiredand
otherregulationsimposedoverlast3years
10/13/16 22
![Page 23: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/23.jpg)
Sample Size Requirement in New Drug Registration – China (May change with new draft legislation)
10/13/16 ©MRCT 23
Current China Regulatory Policies for the Registration - Interpretation
•如果不考虑在中国注册上市:样本量无要求(No requirement for sample size if not considering China registration)
•MRCT数据用于国内上市注册(首先在国外上市)(MRCT data and results for China registration, must be used for approval (and approved) in overseas)
– 如果中国部分结果与总体结果一致, 则按照进口药品注册的临床试验要求(If China subgroup results are consistent with overall results, then China registration needs:)
• 药代+至少100对受试者 (100 pairs + PK/PD)
– 如果中国部分结果与总体结果不一致,则按照适宜的桥接策略或重新进行针对中国人群的临床试验(要求具有统计显著性)(If China subgroup results are NOT consistent with overall results, then China registration needs a independent phase III trial with statistical significance)
![Page 24: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/24.jpg)
HowtheUSFDAhasevolvedinConsideringMRCTs
• FollowingICH-E51,FDAdoesnotrequirestudiesthatareconductedsolelyoutsidetheU.S.tobeperformedunderanInvestigationalNewdrugApplication(IND)IntheU.S.,CFR21.314.106governswhichforeigndataareacceptable.
• localdataisnotneeded ifthreecriteriaaremet:– Theforeigndatamustbe“relevantandapplicable”totheUSpopulation.– Theforeignstudiesmustbeperformedbycompetentinvestigators.– TheFDAmusthaveconfidenceinandtheabilitytovalidateorverifythe
data.3
– AnapplicationbasedsolelyonforeignclinicaldatamaybeapprovedifdataareapplicabletotheUSpopulationandmedicalpractice.
– TheFDAmayrequirea“bridgingstudy”ifitisconcernedabouttheapplicabilityofastudy’sresultstoitspopulation.4
1. Khin,etal.“RegulatoryandScientificIssuesRegardingUseofForeignDatainSupportofNewDrugApplicationsintheUnitedStates:AnFDAPerspective,”Nature2. Food,DrugsandCosmeticsActof1938,mostrecentlyamended20163. 21CFR314.106.Theacceptanceofforeigndatainanewdrugapplication.4. ChinandBairu,“GlobalClinicalTrials:EffectiveImplementationandManagement“,AcademicPress2011
24
![Page 25: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/25.jpg)
UnitedStatesFDA(Cont’d)
• Canaskfora“bridgingstudy”ifconcernsabouttheapplicabilityofastudy’sresultstoitspopulation
• Inthecaseofclearevidenceofanethnicdifference,separatetrialsarehighlyrecommendedsoregionalconsiderationscanbeincorporatedintothedesign;thetrialcanbeconductedtocontrolextrinsicfactorsenterastudypopulationwithrelativelyhomogenousintrinsicfactors
1.Khin,etal.“RegulatoryandScientificIssuesRegardingUseofForeignDatainSupportofNewDrugApplicationsintheUnitedStates:AnFDAPerspective,”Nature
![Page 26: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/26.jpg)
FDA’sreviewofMRCT’sgenerallyinvolvesevaluationofstudyresults(statisticalanalyses)accordingtoregion/country
• Evaluatethestudydataandtheconductandkeymetricsofquality
• Evaluate statisticaldisplaysofkeysourcesofvariation,biasanduncertainty
• Regionalandsiteoutcomesevaluated:– Dropouts,differencesinresponserates,outcomes,covariates,exposures,follow-up,concomitantdrugs
• Individualpatientprofileswithinsites- whichsitesandwhichpatientrecordstoevaluateinmoredetail- possibleauditingstrategies(usuallyreliesonelectronicrecords)
• Possiblyintrinsicfactors(markers,gender,ethnicity)orpossiblyextrinsicfactors)recruitmentpatterns,medicalsupportsystem,standardsofcare
• Aligninspectionwithreviewofdataandinsightsforaudits
![Page 27: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/27.jpg)
Interpretationoftheglobalestimateandregionspecificestimatesischallenging
andthecausesforheterogeneity
• Interpretationoftheglobalestimateandregionandspecificestimatesischallenging
• Oftenthecauseofheterogeneity(variabilitybetweenregions)isunknown
• Differencesintreatmenteffectsareexpected;however,toomuchheterogeneityisproblematic
• ArethesetreatmentdifferencesrealandaretheysystematicinthesensethattreatmenteffectsareconsistentlybetterorworseintheU.S.andwhatarethereasonsforit
WhatUSFDAconsiderswhenencounteringheterogeneity
![Page 28: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/28.jpg)
StudyundertakenbyFDAstatisticianstoevaluatepossibilityofsystematicregionaldifferences
• Majorcardiovascularoutcomestudiesevaluatedoverthelast10years
• Overallstudyresultstatisticallypositive,ie.demonstratedoveralleffect
• Regionneverpre-specifiedasafactortobeevaluatedstatistically
• 24independentstudies
![Page 29: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/29.jpg)
In 16/24 studies, the effect was less in US
P = 0.023
P = 0.007
![Page 30: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/30.jpg)
“Heterogeneity” could be observed by chance
30
When fraction of Japanese is 6.7%, negative treatment effect is observed in Japanese with probability of ~20% by chance
![Page 31: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/31.jpg)
Example: What should we do when difference is observed between Japanese & overall?
Basic Principles on Global Clinical Trials (Reference Cases)
• the reason for the difference should be considered by using data such as subgroup analysis
– not enough to conclude that difference is chance finding without any exploration
– one approach could be to evaluate to evaluate the difference in background characteristics between Japanese and overall population & to assess effect of the difference on efficacy results by using subgroup analysis in overall population
31
![Page 32: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/32.jpg)
AnExample:Toprol–XL;theCurrentDrugLabel;“ClinicalTrials”
MERIT-HFwasadouble-blind, placebo-controlled studyofToprol-XLconducted in14countries including theUS.Itrandomized 3991patients(1990toToprol-XL)withejectionfraction </=0.40andNYHAClassII-IVheartfailureattributabletoischemia,hypertension,orcardiomyopathy.
Theprotocolexcludedpatientswithcontraindications tobeta-blockeruse,thoseexpectedtoundergoheartsurgery,andthosewithin28daysofmyocardial infarctionorunstableangina.
Theprimaryendpoints ofthetrialwere(1)all-causemortalityplusall-causehospitalization (timetofirstevent),and(2)all-causemortality.
![Page 33: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/33.jpg)
The trial was terminated early for a statistically significant reduction in all-cause mortality (34%, nominal p=0.00009). …The figure below illustrates principal results for a wide variety of subgroup comparisons, including US vs. non-US populations (the latter of which was not pre-specified). The combined endpoints of all-cause mortality plus all-cause hospitalization and of mortality plus heart failure hospitalization showed consistent effects in the overall study population and the subgroups, including women and the US population. However, in the US subgroup and women, overall mortality and cardiovascular mortality appeared less affected. Analyses of female and US patients were carried out because they each represented about 25% of the overall population. Nonetheless, subgroup analyses can be difficult to interpret and it is not known whether these represent true differences or chance effects.
MERIT-HFResults
![Page 34: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/34.jpg)
![Page 35: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/35.jpg)
35
HowtoAssessConsistencyinanMRCT?
![Page 36: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/36.jpg)
“Trend”AnalysisLinkagetoConsistency
Benefit
Risk
Overall Population
Overall Population
Benefit
Risk
Consistent
Consistent
Consistent
Safetyrisksobservedfromsubpopulation/region
EfficacybenefitobservedfromasubpopulationorInaregion
![Page 37: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/37.jpg)
“Trend”AnalysisInterpretation&Elaboration- LinkagetoConsistency
Benefit
Risk
Overall Population
Overall Population
Benefit
Risk
Consistent?
Consistent?
Consistent?
Safetyrisksobservedfromsubpopulation
Efficacybenefitobservedfromsubpopulation
![Page 38: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/38.jpg)
“Trend”AnalysisInterpretation&Elaboration- LinkagetoConsistency
Similarrisks
Similarefficacy
PositiveTrend
Similarrisks
Betterefficacy
PositiveTrend
Chinesesubpopulation vs.overallpopulationinapositivetrial
Lowerrisks(?)
Similarefficacy
PositiveTrend
√
√
√Lowerrisks(?)
Lowerefficacy
PositiveTrend(?) ?
![Page 39: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/39.jpg)
39
ConsistencyAssessmentinMRCT- LevelofConsistencywithStatisticalMethods
![Page 40: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/40.jpg)
Consistency and Disease Categories
Consistency should be considered with different disease settings. Considering medical needs and potential impact of ethnic factors in clinical practice, three different disease categories may be considered:
Category 1: Unmet medical needs and/or rare disease
Category 2: Common disease without potential ethnic differences
Category 3: Common disease with potential ethnic differences
10/13/16 ©MRCT 40
![Page 41: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/41.jpg)
Consistency and Disease Categories
Consistency should be considered with different disease settings. Considering medical needs and potential impact of ethnic factors in clinical practice, three different disease categories may be considered:
Category 1: Unmet medical needs and/or rare diseaseSame trend required
Category 2: Common disease without potential ethnic differencesTreatment effect proportional
Category 3: Common disease with potential ethnic differences Treatment effect in region demonstrates clinicalsignificance with statistical rigor.
10/13/16 ©MRCT 41
![Page 42: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/42.jpg)
42
Disease Category 1
• Level1consistencyrequired:toassessregionaltreatmenteffectindiseasewithunmetmedicalneeds,e.g.,HIV/AIDS,somemalignanttumor,raredisease,etal.
Disease Category 2
• Level2consistencyrequired:toassessregionaltreatmenteffectforcommondiseasewithnoevidenceofpotentialethnicdifferenceintreatment.Inthissetting, certainregionaleffectsizeisrequired
Disease Category 3
• Level3consistencyrequired: toassessregionaltreatmenteffectforcommondiseasewithevidenceofpotentialethnicdifferenceintreatment. Inthissettingclinicalsignificancewithstatistical rigorofregional treatmenteffectisrequired.
Level of Consistency for Different Disease Categories
Equivalency Proportionality Clinical significance with statistical rigor
![Page 43: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/43.jpg)
Level1
Level2
Level3
Statistical Rigor
Quantitative
Qualitative
LevelofConsistency:from“weak”to“strong”定量
定性
统计学严谨性
![Page 44: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/44.jpg)
Level1Consistency;ObservationaltrendAlltreatmenteffects>0
10/13/16 ©MRCT 4444
![Page 45: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/45.jpg)
Level2Consistency,Treatmenteffectsareproportional;Atleast50%retention
10/13/16 ©MRCT 4545
![Page 46: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/46.jpg)
Level 3 Consistency,Treatment effect in region demonstrates clinical significance with statistical rigor.
10/13/16 ©MRCT 46
10# 10#
7#
0#1#2#3#4#5#6#7#8#9#
10#11#
Global#Effect# Regional#Effect#Example#
Regional#Effect#Example#
Treatment(Effect(
46
![Page 47: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/47.jpg)
Level3Consistency:Overalltreatmenteffectsandforregionachieveclinicalsignificancewithstatisticalrigor
• Toachievestatisticalrigorforbothoverallandregionalsubgroup,useeitherdatawithinMRCTOR datafromMRCTplusanextensiontrial, ifthesamplesizeintheMRCTisnotadequatetoassessclinicallymeaningfultreatmenteffectwith statisticalrigor.
• Toachievestatisticalrigorfortheregionalresults, informationfortheregionanalysismaycombinebothregioninformationandtheinformationborrowedfromotherregions.Theinformationborrowedwillbedown-weighted
10/13/16 ©MRCT 47
MRCT
NTETE
ExtensionofMRCT
TE
NTE(down-weighted when
combined for analyses)
TE
Where:TE: targeted ethnic groupNTE: non-targeted ethnic group
![Page 48: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/48.jpg)
Conclusions
IncreasinguseofMRCTdesigninworldwidedrugdevelopment
• Toexpeditesimultaneous newdrugdevelopmentwithgreaterpatientpopulations
• Tomaintainthesamelevelofscientificrigorinthetrialdesignwhentheoutcomesarepresentedtodifferentregulatoryagenciesforevaluation
• Positiveresultsandbenefit/riskratioofMRCTprovidesolidbasis forthetotalityofevidenceforanewdrugregistrationglobally
Opportunities
• Continuerefinementofconsiderationofrequirementsfor“consistency”
• Enhancepost-approvalmonitoringandpharmacovigilance globally
• RegulatoryconvergencesurroundingcountryspecificrequirementsforMRCTs
![Page 49: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/49.jpg)
MRCT– theOpportunityandPromise
• AdvancingthepracticeofMRCTsgloballywillsupportsimultaneousglobalsubmissions– Shiftingfocusfrompatientnumberrequirementstoaregionalperspectiveofthetotalstudypopulationsizedrivenbythestudyobjectiveandoverallhypothesis
– Emphasisonregulatorydecisionsbasedonbenefit-riskofdiseasestate,patientpopulation,unmetmedicalneedindeterminationofPhase3requirements
10/13/16 ©MRCT 49
![Page 50: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/50.jpg)
QuestionsforDiscussion
• WhenconductinganMRCT withsequentialparticipantsenrolled,– Whatistheimpactontheoverallresults?– Arethecountry/regionalresultsaloneinterpretable?
• WheninterpretingtheregionalresultsinMRCT– Ifvariabilityexists,howtointerpretand/ordealwithit?Validityissueor
Qualityissueorboth?• Extrapolationoftreatmenteffects toChinapopulationwithheterogeneity(QuantitativeandQualitative) oftreatmenteffectsamongregions/Countries.
• Interpretationoftreatmenteffects:whichfactor(s)mostimportanttoevaluaterelationshipoftreatmenteffects:Site/center/clinic,Country,Region?
50
![Page 51: Multi-Regional Clinical Trials (MRCTs): Practice and ......patient characteristics, or clinical settings.” • ICH-E9 Statistical Principles for Clinical Trials – Protocol implementation](https://reader034.fdocuments.us/reader034/viewer/2022042515/5f39de80d1d8f4160c046f2f/html5/thumbnails/51.jpg)
Thankyou
10/13/16 51